Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Abstract

RNA interference (RNAi) holds considerable promise as a therapeutic approach to silence disease-causing genes, particularly those that encode so-called ‘non-druggable’ targets that are not amenable to conventional therapeutics such as small molecules, proteins, or monoclonal antibodies. The main obstacle to achieving in vivo gene silencing by RNAi technologies is delivery. Here we show that chemically modified short interfering RNAs (siRNAs) can silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice. Administration of chemically modified siRNAs resulted in silencing of the apoB messenger RNA in liver and jejunum, decreased plasma levels of apoB protein, and reduced total cholesterol. We also show that these siRNAs can silence human apoB in a transgenic mouse model. In our in vivo study, the mechanism of action for the siRNAs was proven to occur through RNAi-mediated mRNA degradation, and we determined that cleavage of the apoB mRNA occurred specifically at the predicted site. These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Biodistribution of siRNAs in liver and jejunum.
Figure 2: In vivo silencing of murine apoB mRNA by siRNAs in wild-type mice.
Figure 3: Effects of siRNA administration on apoB-100 protein levels.
Figure 4: Therapeutic reduction of lipoprotein and cholesterol levels after siRNA treatment.
Figure 5: In vivo silencing of murine and human apoB mRNA in mice transgenic for human apoB.
Figure 6: siRNA-mediated cleavage of apoB mRNA in vivo

References

  1. 1

    Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161–164 (2004)

    ADS  CAS  Article  Google Scholar 

  2. 2

    Scherr, M., Battmer, K., Dallmann, I., Ganser, A. & Eder, M. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 13, 353–363 (2003)

    CAS  Article  Google Scholar 

  3. 3

    Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 9, 347–351 (2003)

    CAS  Article  Google Scholar 

  4. 4

    Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210–216 (2003)

    CAS  Google Scholar 

  5. 5

    Zhang, X. et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279, 10677–10684 (2004)

    CAS  Article  Google Scholar 

  6. 6

    Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004)

    Article  Google Scholar 

  7. 7

    Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P. & Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975–4977 (2004)

    CAS  Article  Google Scholar 

  8. 8

    Burnett, J. R. & Barrett, P. H. Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit. Rev. Clin. Lab. Sci. 39, 89–137 (2002)

    CAS  Article  Google Scholar 

  9. 9

    Farese, R. V. Jr, Ruland, S. L., Flynn, L. M., Stokowski, R. P. & Young, S. G. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl Acad. Sci. USA 92, 1774–1778 (1995)

    ADS  CAS  Article  Google Scholar 

  10. 10

    Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986)

    ADS  CAS  Article  Google Scholar 

  11. 11

    Glueck, C. J. et al. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. Metabolism 46, 625–633 (1997)

    CAS  Article  Google Scholar 

  12. 12

    Enjoji, M., Wang, F., Nakamuta, M., Chan, L. & Teng, B. B. Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. Hum. Gene Ther. 11, 2415–2430 (2000)

    CAS  Article  Google Scholar 

  13. 13

    Linton, M. F. et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92, 3029–3037 (1993)

    CAS  Article  Google Scholar 

  14. 14

    Purcell-Huynh, D. A. et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95, 2246–2257 (1995)

    CAS  Article  Google Scholar 

  15. 15

    Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635–637 (2003)

    CAS  Article  Google Scholar 

  16. 16

    Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genet. 34, 263–264 (2003)

    CAS  Article  Google Scholar 

  17. 17

    Llave, C., Xie, Z., Kasschau, K. D. & Carrington, J. C. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 20, 2053–2056 (2002)

    ADS  Article  Google Scholar 

  18. 18

    Yekta, S., Shih, I. H. & Bartel, D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594–596 (2004)

    ADS  CAS  Article  Google Scholar 

  19. 19

    Damha, M. J. & Ogilvie, K. K. Oligoribonucleotide synthesis. The silyl-phosphoramidite method. Methods Mol. Biol. 20, 81–114 (1993)

    CAS  PubMed  Google Scholar 

  20. 20

    Iyer, R. P., Egan, W., Regan, J. B. & Beaucage, S. L. 3H–1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253–1254 (1990)

    CAS  Article  Google Scholar 

  21. 21

    Zlot, C. H. et al. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40, 76–84 (1999)

    CAS  PubMed  Google Scholar 

  22. 22

    Hammad, S. M. et al. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 52, 916–921 (2003)

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank P. Sharp for his advice and creative input. We are grateful to J. Maraganore and T. Ulich for their support and encouragement. We would like to thank S. Young for the LF3 anti-mouse apoB antibody; D. Bartel and S. Yekta for advice on the 5′-RACE assay; S. Young and M. Stoffel for valuable discussions; and LipoFIT Analytic GmbH and the Institute for Biophysics and Physical Biochemistry of the University of Regensburg for the characterization of lipoprotein particles by NMR. For technical assistance we thank P. Deuerling, F. Hertel, S. Leuschner, N. Linke, A. Müller, G. Ott, H. Schübel, S. Shanmugam, M. Duckman and C. Auger.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jürgen Soutschek.

Ethics declarations

Competing interests

All authors are employees of Alnylam.

Supplementary information

Supplemental Figure 1

Specificity of apoB mRNA reduction in wild-type mice. siRNA-mediated reduction of apoB mRNA in liver mRNA pools from wild-type mice that received saline (n=10), Chol-mismatch-siRNA (n=10), and Chol-apoB-1-siRNA (n=10). The apoB mRNA was normalized to 4 reference mRNAs: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), glucose-6-phosphatase (G-6-P), factor VII (FVII) and vascular endothelial growth factor (VEGF). Data represent the mean of three independent measurements. Error bars illustrate the standard deviation of the mean. (JPG 18 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004). https://doi.org/10.1038/nature03121

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing